Abstract
Cytomegalovirus (CMV) is one of the most common opportunistic infections seen in patients after cardiac transplantation. Systemic prophylaxis is standard of care in all cardiac transplant recipients. Valganciclovir was adopted for its improved bioavailability, and it has now replaced oral ganciclovir for CMV prophylaxis in many centers. The current recommended dosage of valganciclovir for CMV prophylaxis is 900 mg daily for at least 100 days after cardiac transplantation for patients with stable renal function.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
